• Version
• Download 1067
• File Size 515.83 KB
• File Count 1
• Create Date August 24, 2021
• Last Updated October 6, 2026

Demanding Access to Existing and Upcoming Gene Therapies for Beta Thalassaemia

The Thalassaemia International Federation (TIF) expresses its deep disappointment at bluebird bio’s decision to wind down its European operations and make Zynteglo™, its gene therapy for beta-thalassaemia, available exclusively in the United States.

Attached Files